FindTrial
Sign In

Generation of broadly neutralizing antibodies for the development of an enterovirus immunotherapy

Generation of broadly neutralizing antibodies for the development of an enterovirus immunotherapy - THEIS Study

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON45608
Enrollment
25
Registered
2017-01-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

enterovirus infections viral infections

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age of 18-65 yrs. Healthy condition (no immunodeficiency). Written informed consent.

Exclusion criteria

Exclusion criteria: see above

Design outcomes

Primary

MeasureTime frame
From each donor blood will be withdrawn in order to collect serum and PBMCs. The sera will be used to determine nAb titers against a panel of clinically relevant EVs, using a cytopathic effect (CPE) reduction assay. On the basis of the neutralizing activity in the sera, paired PBMC samples will be selected for isolation of bNAb producing B cells by single cell sorting.—

Secondary

MeasureTime frame
None—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)